660 results about "Mesenchymal stem cell" patented technology

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention relates to injectable temperature-sensitive hydrogel loaded with traditional Chinese medicine active exosomes, and belongs to the technical field of clinical treatment of diabetic foot refractory wounds, and the injectable temperature-sensitive hydrogel is obtained by poloxamer 407 hydrogel and a hyaluronic acid loaded composite carrier; the composite carrier body is formed by coating a traditional Chinese medicine active exosome with a coating solution; the traditional Chinese medicine active exosome is obtained by inducing adipose-derived mesenchymal stem cells with a modified astragalus extract. The injectable temperature-sensitive hydrogel is obtained by loading a composite carrier with poloxamer 407 hydrogel and hyaluronic acid, the poloxamer 407 and the hyaluronic acid quickly form a physical barrier on a wound surface after being injected, a moist healing environment is provided, and continuous and slow release of exosome and active ingredients is realized by means of the temperature-sensitive characteristic and the network structure of the poloxamer 407 and the hyaluronic acid, so that the wound healing effect is improved. And over-high local concentration or premature loss caused by sudden release of the medicine is avoided.

The invention discloses a temperature-sensitive hydrogel loaded with mesenchymal stem cell exosome as well as a preparation method and application of the temperature-sensitive hydrogel, and belongs to the technical field of biological medicines. The method comprises the following steps: (1) adding poloxamer 407 into a pre-cooled dispersion medium to enable the final mass concentration to be 20-30%, and oscillating and dissolving at 4 DEG C overnight to obtain poloxamer hydrogel; (2) collecting a mesenchymal stem cell culture supernatant, and then centrifuging, wherein the centrifuging condition is 200 * g * 15 minutes to 2000 * g * 20 minutes to 12000 * g * 20 minutes; filtering the supernatant, concentrating by using an ultrafiltration tube, further performing ultracentrifugation on the concentrated solution, re-suspending the precipitate by using DPBS, centrifuging again, and re-suspending the finally obtained exosome precipitate by using DPBS to obtain an exosome suspension; the ultracentrifugation condition is as follows; and (3) taking the poloxamer hydrogel prepared in the step (1), adding the exosome suspension obtained in the step (2) under an ice-water bath condition, and uniformly mixing to obtain the poloxamer temperature-sensitive hydrogel.

The invention belongs to the technical field of exosome freeze-dried powder, and discloses exosome freeze-dried powder and a preparation method thereof, the exosome freeze-dried powder contains mesenchymal stem cell exosome, trehalose, sodium hyaluronate, hydroxypropyl-beta-cyclodextrin, glutathione, ceramide and fructo-oligosaccharide. According to the exosome freeze-dried powder, hydroxypropyl-beta-cyclodextrin, glutathione, ceramide and fructo-oligosaccharide are added, the membrane structure integrity of the exosome is effectively protected, the retention rate of active substances in the exosome freeze-dried powder is high, and therefore the effects of resisting inflammation, regulating cell metabolism, promoting tissue repair and the like of the exosome can be fully exerted. In addition, glutathione can directly remove skin free radicals and inhibit oxidative stress injury, and has an anti-oxidation effect; ceramide can also supplement skin lipid barrier, enhance the water locking capacity and enhance the moisturizing effect of sodium hyaluronate; fructo-oligosaccharide can also regulate skin micro-ecological balance, and has anti-inflammatory and bacteriostatic effects.

The invention relates to the cross technical field of biological medicine and image processing, and discloses a mesenchymal stem cell aging detection method based on image processing. The method comprises the following steps: automatically collecting bright field and multi-channel fluorescence images in an integrated cell culture monitoring device; after background correction and illumination homogenization, segmenting the cells by using a U-Net network and extracting single cell contours; calculating characteristics such as cell area, roundness, cytoplasmic ratio, nuclear form irregularity index, lysosome fluorescence intensity mean value and distribution entropy; and inputting a gradient boosting decision tree model to judge the unicellular aging state, and evaluating population aging with a 20% positive rate threshold. According to the invention, label-free, non-invasive and high-flux accurate detection is realized, and the method is superior to manual interpretation.

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

The invention discloses application of a 3D hypoxia mesenchymal stem cell derived exosome preparation in preparation of an immune cell proliferation inhibitor or a medicine for treating acute myocardial infarction, belongs to the technical field of biology, and solves the problems of low cell survival rate and immunological rejection in application of a cell treatment method in the prior art. The 3D hypoxia mesenchymal stem cell derived exosome is used as a medium for treating acute myocardial infarction, and the problem of immunological rejection can be solved.

The invention relates to a bioactivity-related characteristic marker of umbilical cord mesenchymal stem cell-derived small extracellular vesicles and application of the bioactivity-related characteristic marker. The bioactivity-related characteristic marker of the umbilical cord mesenchymal stem cell-derived small extracellular vesicles comprises one or a combination of more than two of a PSMB3 protein, an SAA4 protein, a VPS33B protein and an AKR7A2 protein. The invention provides a screening method of the characteristic markers, and particularly, the biological activity of the human umbilical cord mesenchymal stem cell source extracellular vesicles can be effectively judged by detecting the characteristic markers or the combination of the characteristic markers of the umbilical cord mesenchymal stem cell source extracellular vesicles. An evaluation means and an important reference are provided for product quality control, clinical transformation and the like based on the umbilical cord mesenchymal stem cell-derived small extracellular vesicles.

The invention discloses a preparation method of a growth factor gradient bionic scaffold for tendon-bone interface regeneration and repair, and belongs to the technical field of biomedical materials. The composite scaffold is constructed by adopting a coaxial electrospinning and self-assembly technology, and is compounded by a core-shell oriented nanofiber layer and a non-oriented nanofiber layer through a gelatin adhesive to respectively simulate tendon phase and bone phase structures of a tendon-bone interface; a shell layer of the tendon-phase-simulated core-shell oriented nanofiber is a PCL layer containing CTGF, a core layer of the tendon-phase-simulated core-shell oriented nanofiber is a PVA layer containing TGF-beta1, and a bone-phase-simulated non-oriented nanofiber layer is a PCL / Gel co-spun layer containing BMP-2 polylactic acid microspheres and nano-hydroxyapatite. The scaffold can realize secondary controlled release of early-stage release of CTGF, slow release of TGF-beta1 in the middle and later periods and continuous release of BMP-2, and cooperates with a fiber orientation structure to induce graded differentiation of mesenchymal stem cells and promote integrated repair of a tendon-bone interface gradient structure, so that the problems of poor healing of a tendon-bone interface and high repeated fracture rate in a traditional repair method are solved, and the scaffold has good application prospects. The important application value is realized in the field of tendon-bone injury treatment in sports medicine.

The invention discloses a PDRN-loaded umbilical cord mesenchymal stem cell source nano-vesicle and a preparation method thereof, and belongs to the technical field of biological medicines. The preparation method provided by the invention comprises the following steps: mixing an umbilical cord mesenchymal stem cell suspension with a PDRN solution, and carrying out freeze thawing treatment; incubating the mixed solution subjected to freeze thawing treatment; extruding the incubated mixed solution for multiple times by using a filter membrane; and collecting the extruded product, and separating and purifying to obtain the PDRN-loaded umbilical cord mesenchymal stem cell source nano-vesicle. According to the preparation method disclosed by the invention, the encapsulation efficiency of PDRN is remarkably improved, meanwhile, secondary damage of a traditional post-loading technology to a preformed vesicle structure is avoided, the membrane integrity and biological activity of a final product are better maintained, the yield is high, and the preparation process is rapid; the introduction of exogenous impurities is avoided from the source, and the high purity and biological safety of the obtained nano-vesicle component are ensured.

The application discloses a polypeptide composition for treating obesity and related metabolic diseases and application thereof. The polypeptide composition comprises polypeptide 1 and polypeptide 2, wherein the amino acid sequence of the polypeptide 1 is shown as SEQ ID NO. 1, can be specifically combined with the CD105 receptor on the surface of MSCs and the AdipoR1 receptor of adipocytes; the amino acid sequence of the polypeptide 2 is shown as SEQ ID NO. 2, can target adipose tissue and regulate glycolipid metabolism. The polypeptide composition is combined with fat-derived mesenchymal stem cells (MSCs) and applied to a high-fat-diet obese mouse model, and the results show that the composition has a significant synergistic effect in reducing body fat, improving the morphology of adipose tissue, regulating serum metabolic factors and inflammatory factors, and has no obvious organ toxicity. The application provides a new effective strategy and a safe and reliable pharmaceutical composition for treating obesity and related metabolic diseases.

The invention relates to the technical field of biomedical information, in particular to an umbilical cord mesenchymal stem cell donor matching database construction method based on HLA (human leukocyte antigen) typing, which comprises the following steps of: recording and storing data of a donor in a database to finish initial construction of the database; regularly rechecking the donor data record stored in the database, and updating the state identifier of the donor data record when the rechecked data is changed by a preset degree; and receiving a matching request containing the human leukocyte antigen typing data of the target patient and the target disease type, performing donor screening in the database by using a preset comprehensive matching degree model based on the matching request, and optimizing parameters of the comprehensive matching degree model through a machine learning model based on the matching record and the clinical curative effect data corresponding to the matching record. According to the method, the accuracy and effectiveness of umbilical cord mesenchymal stem cell treatment are improved, and meanwhile, the system has continuous self-evolution ability.

The present application relates to the technical field of stem cell medicine, in particular to a mesenchymal stem cell composition for treating prostate diseases and a preparation method and application thereof. The mesenchymal stem cell composition for treating prostate diseases comprises mesenchymal stem cells treated by low oxygen and an anti-inflammatory peptide WYPWMKKHHRRRRRRRRR. The prostate diseases are selected from prostatitis, prostate calcification, sexual function improvement, frequent urination and urgency, etc. The mesenchymal stem cell composition can significantly improve the symptoms of prostate diseases, and the curative effect is remarkable.

The invention relates to the field of cell engineering and gene engineering, in particular to a method for enhancing the multiplication capacity of umbilical cord mesenchymal stem cells and application. The expression or activity of the STN1 gene in the umbilical cord mesenchymal stem cells is reduced through an accelerant, and the umbilical cord mesenchymal stem cells with enhanced multiplication capacity are obtained. By knocking down the hUC-MSCs of STN1, the proliferation speed of the hUC-MSCs is higher, DNA replication is more active, the clone formation ability is higher, and the aging proportion of the hUC-MSCs can be remarkably reduced.

To provide ectodermal mesenchymal stem cells and methods for producing the same.SOLUTION: A method for producing ectodermal mesenchymal stem cells includes the step of selectively collecting, from peripheral blood of a subject administered with a peptide composed of an amino acid sequence of SEQ ID NO: 1, either (a) PDGFRα-positive and CD34-positive cells or (b) PDGFRβ-positive and CD34-positive cells.SELECTED DRAWING: None

Provided herein are immortalized mesenchymal stem cells comprising a replicating recombinant retrovirus. Methods for treating a cell proliferative disorder using these immortalized mesenchymal stem cells are also provided.

This invention discloses recombinant umbilical cord mesenchymal stem cells related to pentamericin 3 in the field of genetic engineering, their preparation method, and applications. The technical problem this invention aims to solve is how to provide a cell product capable of treating bone regeneration insufficiency. To solve this technical problem, this invention provides recombinant umbilical cord mesenchymal stem cells, which are prepared according to a method comprising the following steps: upregulating or enhancing or increasing the content and / or activity of pentamericin 3 or the expression of the gene encoding said protein in the umbilical cord mesenchymal stem cells, thereby obtaining the recombinant umbilical cord mesenchymal stem cells. The recombinant umbilical cord mesenchymal stem cells provided by this invention can be used to treat diseases related to bone regeneration insufficiency.

This invention belongs to the field of biomedical materials technology, and particularly relates to an analgesic microneedle patch, its preparation method, and its application. The analgesic microneedle patch of this invention uses extracted mesenchymal stem cell exosomes and ginger exosomes as analgesic active substances, and by combining them with microneedle patch technology, it provides a new technical approach for surface anesthesia. The analgesic microneedle patch of this invention combines microneedle technology and photopolymerization 3D printing technology to develop a customizable hydrogel microneedle patch, achieving minimally invasive and precise percutaneous delivery of local anesthetics, providing a new technical approach for surface anesthesia.

The invention discloses a culture method for inducing high expression of umbilical cord mesenchymal stem cells (LRP1) and application, and belongs to the technical field of biological medicines. The technical problem to be solved is to provide a standardized culture method for directionally inducing a specific functional phenotype cell population, so that efficient and accurate induction of LRP1 high-expression UCMSCs is realized, and clinical adaptation is met. According to the key point of the technical scheme, the culture method for inducing the LRP1 high-expression umbilical cord mesenchymal stem cells comprises the following steps: inoculating umbilical cord mesenchymal stem cells into a culture dish at the inoculation density of 5.5 * 10 < 3 > / cm < 2 > to 3.6 * 10 < 4 > / cm < 2 >, and culturing for 24-72 hours by using a special mesenchymal stem cell culture medium without adding a supplement, so that the acquisition efficiency of the LRP1 high-expression UCMSCs is improved, and the yield of the LRP1 high-expression UCMSCs is increased. Antibody labeling and flow sorting are not needed, so that the operation steps are simplified, and the complexity and cost of the culture process are reduced.

The invention provides a culture medium for improving Klotho protein secreted by mesenchymal stem cells and application of the culture medium, and particularly, the culture medium comprises a basic culture medium, statins and a ROCK inhibitor. The culture medium can effectively improve the Klotho protein secretion level of the mesenchymal stem cells, does not affect the biological activity of the mesenchymal stem cells, and ensures the biological function integrity of the mesenchymal stem cells; meanwhile, operation is easy, cost is low, and good clinical application value is achieved.

The invention provides an engineered mesenchymal stem cell secreting GLP-1 / GIP dual agonist-Fc fusion protein and application of the engineered mesenchymal stem cell, and belongs to the technical field of biological medicine. The invention provides a GLP-1 / GIP dual agonist-Fc fusion protein. The fusion protein is formed by sequentially connecting four structural functional domains, namely a signal peptide, a human GIP (1-42) active fragment, a human GLP-1 (7-37) A8G mutant and an Fc fragment of human IgG4 through connecting peptides from an N end to a C end. And an engineering MSC cell strain (GE-MSC) which is derived from the iPSC and is used for expressing the GLP-1 / GIP dual agonist functional protein is constructed by adopting a gene editing technology. The invention creates an intelligent living body medicine factory which can be implanted at one time, autonomously target and stably secrete multifunctional therapeutic molecules for a long time, and has a tissue repair capability, so as to overcome multiple limitations of an existing protein medicine on compliance, medicine effect, cost and disease modification capability.

This invention discloses a low-energy laser pretreatment method for enhancing the paracrine function of mesenchymal stem cells. Specifically, the method includes irradiating human umbilical cord mesenchymal stem cells with an 808nm laser. The irradiation parameters are: output power density, irradiation time of 60-120 s per irradiation, continuous irradiation of cells for 3 days, and irradiation twice a day.

Provided is a method for comprehensive evaluation of the biological potency of mesenchymal stem cells, comprising: simulating in vitro a scenario where mesenchymal stem cells enter an inflammatory site in vivo, detecting expression levels of PD-L1, IL-6, HGF, and IDO1 in the mesenchymal stem cells, and detecting inhibition rates of proliferation of immune cells and secretion of inflammatory factor TNF-α, so as to evaluate the immunomodulatory function and tissue regeneration function of the mesenchymal stem cells.

The utility model discloses a mesenchymal stem cell exosome storage device convenient to use, which comprises an anti-skid leg, a temperature control unit is arranged on the top surface of the anti-skid leg, a material taking unit is arranged in the temperature control unit, an adjusting unit is arranged on the top surface of the temperature control unit, a placing unit is arranged on the bottom side of the adjusting unit, and the placing unit comprises a placing plate. The placing plate is arranged on the bottom side of the adjusting unit, a first rotating wheel is rotationally connected into the placing plate, a clamping block is slidably connected into the placing plate, and a plurality of second rotating wheels are rotationally connected into one side of the clamping block. Through the arrangement of the placing plate, the rotating wheel I, the clamping block, the rotating wheel II and the limiting rod, the effect of conveniently and quickly fixing and limiting a test tube for containing exosomes is achieved, and meanwhile, the friction between the test tube and the clamping block is reduced.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The utility model discloses an angle-adjustable rotary tank type mesenchymal stem cell balling device, which relates to the technical field of mesenchymal stem cell balling, is arranged in a temperature control incubator for culturing mesenchymal stem cell balling, and comprises a bottle body for containing mesenchymal stem cells and a container for containing ultrasonic buffer water, the container is fixedly arranged on a horizontal bearing surface in the temperature control incubator, the bottle body is obliquely arranged, the bottom of the bottle body is positioned in the ultrasonic buffer water liquid of the container, the bottle body is driven to move by a driving device fixed on the horizontal bearing surface, and the driving device is configured to enable the bottle body to vibrate back and forth in the container along the horizontal direction and simultaneously drive the bottle body to move back and forth. And the bottle body also rotates around the axial direction of the bottle body. According to the utility model, the culture bottle simultaneously performs compound motion of horizontal oscillation and self rotation, so that the cell growth can be more uniformly stimulated, and the problem of poor balling effect caused by single rotation in the traditional method is solved. Through the movement mode, the cells are distributed more uniformly in the culture solution, and the formed spheres are more consistent in size and higher in quality.

A method of producing hematopoietic stem / progenitor cells (HS / PCs) and blood cells from adipose derived mesenchymal stem cells (Ad MSCs). The method comprises obtaining biological cells of a subject; expanding the biological cells; obtaining a pure Ad MSCs cell line from the expanded biological cells; converting the pure Ad MSCs cell line into HS / PCs in vitro; expanding the converted HS / PCs in vitro; and obtaining the expanded HS / PCs.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The current invention relates to a composition comprising extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs). The EVs are part of a population of particles in the composition having a particle size of between 0.05 and 0.22 micron. The concentration of these particles is at least 1×1011 particles per ml of composition. At least 90% of the particles with particle size of between 0.05 and 0.22 micron are EVs. The EVs are defined by having a concentration of intra-vesicular Annexin V of at least 40 ng / ml and a concentration of extra-vesicular Annexin V of less than 1 ng / ml. Uses of the composition also are disclosed.